Rhinomed Ltd (RNO)

Sydney
0.175
0.000(0.00%)
  • Volume:
    20,917
  • Bid/Ask:
    0.175/0.180
  • Day's Range:
    0.175 - 0.175
Earnings results expected in 13 days

RNO Overview

Prev. Close
0.175
Day's Range
0.175-0.175
Revenue
5.7M
Open
0.175
52 wk Range
0.1-0.482
EPS
-0.03
Volume
20,917
Market Cap
50M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
85,812
P/E Ratio
-
Beta
1.31
1-Year Change
-51.06%
Shares Outstanding
285,719,694
Next Earnings Date
31 Aug 2022
What is your sentiment on Rhinomed?
or
Market is currently closed. Voting is open during market hours.

Rhinomed Ltd News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Rhinomed Ltd Analysis

Rhinomed Ltd Company Profile

Rhinomed Ltd Company Profile

Employees
0
Market
Australia

Rhinomed Limited is an Australia-based wearable nasal and respiratory technology company. The Company is engaged in the research, development and commercialization of consumer and medical devices. It has developed a nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities. The Company’s products include Mute, Turbine, Pronto Sleep, Pronto Clear and Rhinoswab. The Mute is a nasal technology that is designed to allow the user to manage sleep by breathing more and snoring less. The Turbine is designed to fit comfortably inside the nose and gently open each individual nostril to allow more airflow during sport, physical exertion or focused breathing, such as yoga and meditation. Rhinoswab is a patented comfortable, self-administered nasal swab that provides high-yield sampling and fits existing pathology workflows. Pronto Sleep is a vapor inhaler that gently opens the nose and delivers a soothing blend of four pure essential oils.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralBuySellSell
Technical IndicatorsSellSellStrong SellStrong SellStrong Sell
SummaryNeutralNeutralNeutralStrong SellStrong Sell